Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
McKane, Joseph K. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S350000, C514S321000
Reexamination Certificate
active
06852737
ABSTRACT:
The invention describes novel lercanidipine crude Forms (A) and (B), novel lercanidipine hydrochloride crystalline Forms (I) and (II) obtained from said crude Forms, pharmaceutical, antihypertensive compositions containing as active agent at least one of the lercanidipine hydrochloride crystalline Forms (I) and (II) and methods of use thereof.
REFERENCES:
patent: 4285955 (1981-08-01), Wehinger et al.
patent: 4705797 (1987-11-01), Nardi et al.
patent: 4968832 (1990-11-01), Nardi et al.
patent: 5248699 (1993-09-01), Sysko et al.
patent: 5696139 (1997-12-01), Leonardi et al.
patent: 5767136 (1998-06-01), Sartani et al.
patent: 5912351 (1999-06-01), Leonardi et al.
patent: 20010002404 (2001-05-01), Webb et al.
patent: 20010029257 (2001-10-01), Murdock et al.
patent: 20010044584 (2001-11-01), Kensey
patent: 20010056095 (2001-12-01), Mylari
patent: 20020010208 (2002-01-01), Shashoua et al.
patent: 20020015713 (2002-02-01), Murdock et al.
patent: 20020032149 (2002-03-01), Kensey
patent: 20020042405 (2002-04-01), Schuh
patent: 20020061835 (2002-05-01), Kensey
patent: 20020068740 (2002-06-01), Mylari
patent: 20020099046 (2002-07-01), Scott
patent: 20020137755 (2002-09-01), Bilodeau et al.
patent: 0 153 016 (1990-05-01), None
patent: WO 9635668 (1996-11-01), None
patent: WO 9703669 (1997-02-01), None
McClellan and Jarvis, (2000) “Lercanidipine: A Review of its Use in Hypertension”, Adis Drug Evaluation' 60:1 123-1140.*
Leonardi et al. (1998) “AsymmetricN-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine,-3,5-dicarboxylic acids with antihypertensive activity”,Eur. J. Med. Chem.,33:399-420.
McClellan and Jarvis, (2000) “Lercanidipine: A Review of its Use in Hypertension”,Adis Drug Evaluation,60:1123-1140.
(1987) REC 15/2375,Drugs of the Future,12:1113-1115.
Bonifacio Fausto
Campana Francesco
De Iasi Gianluca
Leonardi Amedeo
Coppins Janet L
Darby & Darby
McKane Joseph K.
Recordati Ireland Limited
LandOfFree
Crude and crystalline forms of lercanidipine hydrochloride does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crude and crystalline forms of lercanidipine hydrochloride, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crude and crystalline forms of lercanidipine hydrochloride will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505646